Tokai Pharma (TKAI) Reports Q2 Loss Per Share of $0.40

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Tokai Pharma (TKAI) Reports Q2 Loss Per Share of $0.40

Tokai Pharmaceuticals Reports Second Quarter 2015 Results

August 12, 2015 4:00 PM EDT

Pivotal Phase 3 Trial of Galeterone in AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer on Track for Topline Data by End of 2016

BOSTON--(BUSINESS WIRE)-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing proprietary therapies for prostate cancer and other hormonally driven diseases, today reported results for the quarter ended June 30, 2015.

Tokais business highlights for the quarter include the initiation of ARMOR3-SV, Tokais pivotal Phase 3 clinical trial of galeterone in men with metastatic castration-resistant prostate cancer (mCRPC) whose tumor cells express... More